Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders
Brett L. Roberts, Zhi‐Xiong Ma, Ang Gao, et al.
ACS Chemical Biology (2020) Vol. 15, Iss. 6, pp. 1487-1496
Closed Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Current strategies for the design of PROTAC linkers: a critical review
Robert I. Troup, Charlene Fallan, Matthias G. J. Baud
Exploration of Targeted Anti-tumor Therapy (2020) Vol. 1, Iss. 5
Open Access | Times Cited: 254
Targeted protein degradation: A promise for undruggable proteins
Kusal T. G. Samarasinghe, Craig M. Crews
Cell chemical biology (2021) Vol. 28, Iss. 7, pp. 934-951
Open Access | Times Cited: 187
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 172
Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 170
Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins
Yaxian Zhou, Peng Teng, Nathan T. Montgomery, et al.
ACS Central Science (2021) Vol. 7, Iss. 3, pp. 499-506
Open Access | Times Cited: 151
Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance
Xin Lin, Hua Xiang, Guoshun Luo
European Journal of Medicinal Chemistry (2020) Vol. 206, pp. 112689-112689
Closed Access | Times Cited: 72
A bibliometric analysis of PROTAC from 2001 to 2021
Deping Li, Dongmin Yu, Yan Li, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114838-114838
Closed Access | Times Cited: 66
A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions
Le Guo, Yaxian Zhou, Xueqing Nie, et al.
European Journal of Medicinal Chemistry (2022) Vol. 236, pp. 114317-114317
Open Access | Times Cited: 40
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 25
Innovative, combinatorial and high-throughput approaches to degrader synthesis
Rebecca Stevens, James D. F. Thompson, Julie C. L. Fournier, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 10, pp. 4838-4861
Closed Access | Times Cited: 9
Accelerating PROTACs Discovery Through a Direct‐to‐Biology Platform Enabled by Modular Photoclick Chemistry
Ke‐Nian Yan, Yong‐Qiang Nie, Jiayu Wang, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Open Access | Times Cited: 9
Bispecific Estrogen Receptor α Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening
Jeremy S. Disch, Jennifer M. Duffy, Esther C. Y. Lee, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 8, pp. 5049-5066
Closed Access | Times Cited: 53
Rapid PROTAC Discovery Platform: Nanomole-Scale Array Synthesis and Direct Screening of Reaction Mixtures
Mateusz P. Plesniak, Emilia K. Taylor, Frederik Eisele, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 12, pp. 1882-1890
Closed Access | Times Cited: 20
Integrated Direct-to-Biology Platform for the Nanoscale Synthesis and Biological Evaluation of PROTACs
Rebecca Stevens, Enrique Bendito-Moll, David Battersby, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 22, pp. 15437-15452
Closed Access | Times Cited: 19
VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives
Chao Wang, Yujing Zhang, Jie Wang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113906-113906
Closed Access | Times Cited: 41
PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs
Marı́a Maneiro, Elena De Vita, Daniel Conole, et al.
Progress in medicinal chemistry (2021), pp. 67-190
Closed Access | Times Cited: 36
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Hongyi Zhao, Minhang Xin, San‐Qi Zhang
Drug Development Research (2023) Vol. 84, Iss. 2, pp. 337-394
Closed Access | Times Cited: 16
Reversible Assembly of Proteolysis Targeting Chimeras
Weijun Gui, Sarah F. Giardina, Madeline Balzarini, et al.
ACS Chemical Biology (2023) Vol. 18, Iss. 7, pp. 1582-1593
Closed Access | Times Cited: 16
Direct-to-biology, automated, nano-scale synthesis, and phenotypic screening-enabled E3 ligase modulator discovery
Zefeng Wang, Shabnam Shaabani, Xiang Gao, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 15
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
Nisha Setia, Haider Thaer Abdulhameed Almuqdadi, Mohammad Abid
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116041-116041
Closed Access | Times Cited: 14
Novel approaches for the rational design of PROTAC linkers
Almaz A. Zagidullin, Vasili A Milyukov, Albert A. Rizvanov, et al.
Exploration of Targeted Anti-tumor Therapy (2020) Vol. 1, Iss. 5, pp. 381-390
Open Access | Times Cited: 36
PROTACS: A technology with a gold rush-like atmosphere
Yuwei Wang, Li Lan, Min Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115037-115037
Closed Access | Times Cited: 21
The application of PROTAC in HDAC
Shaoting Chen, Yuxiang Zheng, Benji Liang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115746-115746
Closed Access | Times Cited: 12
Development of Potent and Selective Coactivator-Associated Arginine Methyltransferase 1 (CARM1) Degraders
Haibo Xie, Megan Bacabac, M Ma, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 18, pp. 13028-13042
Open Access | Times Cited: 12
Development of Oligomeric Mannose-6-phosphonate Conjugates for Targeted Protein Degradation
Christopher Μ. Stevens, Yaxian Zhou, Peng Teng, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 6, pp. 719-726
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top